These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28782704)

  • 41. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The management of multidrug-resistant Enterobacteriaceae.
    Bassetti M; Peghin M; Pecori D
    Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Natural History of Carbapenemase-Producing Enterobacterales: Progression From Carriage of Various Carbapenemases to Bloodstream Infection.
    Temkin E; Solter E; Lugassy C; Chen D; Cohen A; Schwaber MJ; Carmeli Y;
    Clin Infect Dis; 2024 Jul; 79(1):22-29. PubMed ID: 38447961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inventory of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in France as Assessed by a Multicenter Study.
    Robin F; Beyrouthy R; Bonacorsi S; Aissa N; Bret L; Brieu N; Cattoir V; Chapuis A; Chardon H; Degand N; Doucet-Populaire F; Dubois V; Fortineau N; Grillon A; Lanotte P; Leyssene D; Patry I; Podglajen I; Recule C; Ros A; Colomb-Cotinat M; Ponties V; Ploy MC; Bonnet R
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterisation of extended-spectrum β-lactamase and AmpC β-lactamase-producing Enterobacteriaceae isolated from companion animals in New Zealand.
    Karkaba A; Grinberg A; Benschop J; Pleydell E
    N Z Vet J; 2017 Mar; 65(2):105-112. PubMed ID: 27973988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
    Tängdén T; Giske CG
    J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
    Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Palacios-Baena ZR; Gutiérrez-Gutiérrez B; De Cueto M; Viale P; Venditti M; Hernández-Torres A; Oliver A; Martínez-Martínez L; Calbo E; Pintado V; Gasch O; Almirante B; Antonio Lepe J; Pitout J; Akova M; Peña-Miralles C; Schwaber MJ; Tumbarello M; Tacconelli E; Origüen J; Prim N; Bou G; Giamarellou H; Bermejo J; Hamprecht A; Pérez F; Almela M; Lowman W; Hsueh PR; Navarro-San Francisco C; Torre-Cisneros J; Carmeli Y; Bonomo RA; Paterson DL; Pascual Á; Rodríguez-Baño J;
    J Antimicrob Chemother; 2017 Mar; 72(3):906-913. PubMed ID: 28062685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.
    Yu WL; Chuang YC; Walther-Rasmussen J
    J Microbiol Immunol Infect; 2006 Aug; 39(4):264-77. PubMed ID: 16926972
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H; Shefler C; Sharma S; Tirosh A; Tal-Jasper R; Kandipalli D; Sharma S; Bathina P; Kaplansky T; Maskit M; Azouri T; Lazarovitch T; Zaidenstein R; Kaye KS; Marchaim D
    Infect Control Hosp Epidemiol; 2015 Aug; 36(8):981-5. PubMed ID: 25990361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden.
    Ostholm-Balkhed A; Tärnberg M; Nilsson M; Johansson AV; Hanberger H; Monstein HJ; Nilsson LE
    Scand J Infect Dis; 2010 Dec; 42(11-12):831-8. PubMed ID: 20608768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014.
    Myat TO; Hannaway RF; Zin KN; Htike WW; Win KK; Crump JA; Murdoch DR; Ussher JE
    Emerg Infect Dis; 2017 May; 23(5):857-859. PubMed ID: 28418298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK; Kim JH; Sohn JW; Yang KS; Kim MJ
    Int J Antimicrob Agents; 2017 Apr; 49(4):410-415. PubMed ID: 28263710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
    Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
    Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013.
    Arnaud I; Maugat S; Jarlier V; Astagneau P;
    Euro Surveill; 2015; 20(36):. PubMed ID: 26536042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.
    Torres-González P; Ortiz-Brizuela E; Cervera-Hernandez ME; Bobadilla-Del Valle M; Martínez-Gamboa A; Sifuentes-Osornio J; Ponce-de-Leon A
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):243-8. PubMed ID: 27519297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
    Bindayna KM; Senok AC; Jamsheer AE
    J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.